These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25445092)

  • 1. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment.
    Sánchez-Moya AI; Daudén E
    Arch Dermatol; 2012 Nov; 148(11):1332-3. PubMed ID: 23165852
    [No Abstract]   [Full Text] [Related]  

  • 3. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
    Jensen JD; Huynh T; Cafardi J; Sami N
    J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
    [No Abstract]   [Full Text] [Related]  

  • 5. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
    Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
    J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case presentation of moderate-severe psoriasis.
    Salmhofer W
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():19-20. PubMed ID: 22758914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
    Gutiérrez-González E; Batalla A; de la Mano D
    Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C.
    Warren RB; Al-Rifai A
    Br J Dermatol; 2013 Mar; 168(3):461-2. PubMed ID: 23445306
    [No Abstract]   [Full Text] [Related]  

  • 12. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis.
    de Unamuno Bustos B; Sánchez RB; Martínez VO; Carazo JL
    Int J Dermatol; 2014 Apr; 53(4):e299-301. PubMed ID: 24262057
    [No Abstract]   [Full Text] [Related]  

  • 14. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis.
    Errichetti E; Piccirillo A
    Eur J Dermatol; 2014; 24(4):508-9. PubMed ID: 25120233
    [No Abstract]   [Full Text] [Related]  

  • 15. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 17. Ustekinumab for the treatment of HIV psoriasis.
    Paparizos V; Rallis E; Kirsten L; Kyriakis K
    J Dermatolog Treat; 2012 Dec; 23(6):398-9. PubMed ID: 21787206
    [No Abstract]   [Full Text] [Related]  

  • 18. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
    Papadavid E; Ferra D; Koumaki D; Dalamaga M; Stamou C; Theodoropoulos K; Rigopoulos D
    Dermatology; 2014; 228(2):107-11. PubMed ID: 24504077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis.
    Javadzadeh S; Gkini MA; Panos GD; Adewoyin T; Bewley A
    Clin Exp Dermatol; 2020 Aug; 45(6):802-804. PubMed ID: 32212270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.